Zydus Lifesciences Reports Strong Q1 Performance with Net Profit of INR 3,396 Million; Consolidated Revenue Hits INR 80,170 Million
Zydus Lifesciences Limited released its unaudited financial results for the quarter ended June 30, 2026, showing strong operational performance. The company's standalone net profit stood at INR 3,396 million. At the group level, Zydus reported total revenue from operations of INR 80,170 million for the quarter.The Board of Directors reviewed and approved the results, which were certified by Deloitte Haskins & Sells LLP, Chartered Accountants.
Standalone Financial Results Snapshot (Q1 FY26)
Zydus Lifesciences recorded significant revenue and profit across its standalone operations in the quarter. The company generated total income of INR 29,959 million for the quarter ended June 30, 2026.The financial performance data comparing the current period with prior periods is detailed below:
| Particulars | Quarter Ended 30/06/2026 (Unaudited) | Quarter Ended 31/03/2026 (Unaudited) | Quarter Ended 30/06/2025 (Unaudited) | Year Ended 31/03/2026 (Audited) |
|---|---|---|---|---|
| Revenue from operations | 28,722 million | 37,409 million | 25,883 million | 114,840 million |
| Total income | 29,959 million | 42,360 million | 27,454 million | 131,515 million |
| Net Profit for the period/year | 3,396 million | 17,220 million | 3,847 million | 35,598 million |
Consolidated Group Performance (Q1 FY26)
The consolidated results highlight robust growth across Zydus's operations. Total revenue from operations for the quarter ended June 30, 2026, was INR 80,170 million. The Group achieved a net profit of INR 9,398 million in the period.The consolidated financial data is as follows:
| Particulars | Quarter Ended 30/06/2026 (Unaudited) | Quarter Ended 31/03/2026 (Unaudited) | Quarter Ended 30/06/2025 (Unaudited) | Year Ended 31/03/2026 (Audited) |
|---|---|---|---|---|
| Total revenue from operations | 80,170 million | 75,870 million | 65,737 million | 271,484 million |
| Total income | 81,231 million | 77,212 million | 67,286 million | 276,579 million |
| Net profit for the period/year | 9,398 million | 12,725 million | 14,668 million | 50,400 million |
Key Operational Developments and Transactions
Zydus Lifesciences reported several significant transactions and operational updates during the reporting period:- Share Buyback: The company successfully extinguished 8,730,158 equity shares on June 18, 2026. This move reduced the paid-up equity share capital by INR 8 million. The aggregate amount paid for the buy back was INR 11,063 million.
- Settlements and Litigation: Zydus Pharmaceuticals Inc. reached a settlement with Indirect Reseller Plaintiffs regarding antitrust lawsuits, with the settlement containing no admission of liability. Separately, Zydus Worldwide DMCC entered into a settlement agreement with Teva Pharmaceutical Industries Ltd., receiving a payment of INR 1,468 million from the Teva Parties.
- Operational Changes: The Group assessed the financial implications of the New Labour Codes, which resulted in a one-time increase in gratuity and leave encashment liability by INR 849 million due to changes in the definition of "wages."
- M&A Activity: Zydus worldwide completed the acquisition of Assertio Holdings, Inc. on June 16, 2026.
The financial results were reviewed by Deloitte Haskins & Sells LLP and detail the company's segment performance across Pharmaceuticals, Consumer products, and Medical technologies.
ZYDUSLIFE Stock Price Movement
Shares of Zydus Lifesciences Limited are rallying to ₹1158.1 as of 2:25 PM, climbing 3.49% in live trading. The stock sees a robust trading volume of 2.08 million shares.Disclaimer: Due care and diligence have been taken in compiling and presenting news and market-related content. However, errors or omissions may arise despite such efforts.
The information provided is for general informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any securities. Readers are advised to rely on their own assessment and judgment and consult appropriate financial advisers, if required, before taking any investment-related decisions.
Any views, opinions, or statements expressed, where applicable, are those of the respective analysts or experts and do not reflect the views of this website. The website has no association with such viewpoints and does not assume any responsibility for them.